Denali Therapeutics Inc. (DNLI) Misses Q1 EPS by 9c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q1 EPS of ($0.80), $0.09 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $35.14 million versus the consensus estimate of $26.88 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Arrive AI and DXC Technology partner to bring delivery tech to factories
• UBS cuts KOSPI target by nearly 10% to reflect higher rates